{"id":"td-pur-inj","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL430074","moleculeType":"Small molecule","molecularWeight":"1769.69"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"While specific mechanistic details are limited in public sources, Td-pur appears to be an investigational immunotherapy targeting tumor-associated antigens or utilizing dendritic cell technology to enhance T-cell mediated anti-tumor immunity. The drug is in Phase 3 development by Boryung Biopharma, a South Korean biopharmaceutical company, suggesting it is being evaluated for oncologic indications.","oneSentence":"Td-pur is an immunotherapeutic injection designed to stimulate anti-tumor immune responses through a purified tumor-associated antigen or dendritic cell-based approach.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:37:39.376Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer immunotherapy (specific indication not publicly confirmed)"}]},"trialDetails":[{"nctId":"NCT04618939","phase":"PHASE3","title":"To Evaluate the Immunogenicity and Safety of 'BR-TD-1001' Administered Intramuscularly in Healthy Children","status":"COMPLETED","sponsor":"Boryung Biopharma Co., Ltd.","startDate":"2016-10-20","conditions":"Diphtheria, Tetanus","enrollment":218}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Td-pur inj","genericName":"Td-pur inj","companyName":"Boryung Biopharma Co., Ltd.","companyId":"boryung-biopharma-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"Td-pur is an immunotherapeutic injection designed to stimulate anti-tumor immune responses through a purified tumor-associated antigen or dendritic cell-based approach. Used for Cancer immunotherapy (specific indication not publicly confirmed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}